Other Secondary End Points
The placebo-corrected absolute and percentage changes from baseline by visit for LDL-C, apoB, non–HDL-C, lipoprotein(a), and total cholesterol levels were not statistically significant at any time point.The reductions in PCSK9 levels from baseline to days 90, 150, and 180 were consistently greater in the inclisiran group than in the placebo group and were statistically significant. The placebo-corrected absolute change in PCSK9 level from baseline to day 180 ranged between −304.4 µg/L (95% CI, −408.0 µg/L to −200.8 µg/L) and −390.4 µg/L (95% CI, −504.5 µg/L to −276.3 µg/L; 